CN114829362A - 一种可用作shp2抑制剂的含氮杂原子的六元并五元芳环衍生物 - Google Patents

一种可用作shp2抑制剂的含氮杂原子的六元并五元芳环衍生物 Download PDF

Info

Publication number
CN114829362A
CN114829362A CN202080069976.8A CN202080069976A CN114829362A CN 114829362 A CN114829362 A CN 114829362A CN 202080069976 A CN202080069976 A CN 202080069976A CN 114829362 A CN114829362 A CN 114829362A
Authority
CN
China
Prior art keywords
group
independently selected
compound
tritium
deuterium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080069976.8A
Other languages
English (en)
Inventor
阳安乐
易韬
王志
张德伟
沈欢
胡凯
王浩
何权鸿
余攀
杨旭东
胡晓
王燕
杨奇
苏忠海
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chengdu Beite Pharmaceutical Co ltd
Original Assignee
Chengdu Beite Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chengdu Beite Pharmaceutical Co ltd filed Critical Chengdu Beite Pharmaceutical Co ltd
Publication of CN114829362A publication Critical patent/CN114829362A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

提供一种如式(I)所示的具有抑制SHP2的活性的化合物、其制备方法，包含该化合物的组合物以及可用作SHP2抑制剂的用途及其制药用途；式(1)中，环A选自3～10元脂环、6～10元芳环、5～10元脂杂环、5～10元芳杂环，环B选自5～8元单杂环、6～12元双杂环、10～18元三杂环、14～20元四杂环，X1、X2、X3各自独立地选自C、N，X4、X5、X6、X7、X8各自独立地选自CR1、N、NR2，L选自共价键、S、CR3R4、NR0、S(O)2、S(O)、O。

Description

PCT国内申请，说明书已公开。

Claims (63)

  1. PCT国内申请，权利要求书已公开。
CN202080069976.8A 2019-12-10 2020-12-08 一种可用作shp2抑制剂的含氮杂原子的六元并五元芳环衍生物 Pending CN114829362A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN2019112582167 2019-12-10
CN201911258216 2019-12-10
CN2020105858546 2020-06-24
CN202010585854 2020-06-24
CN202011197272 2020-10-31
CN2020111972727 2020-10-31
CN202011205423 2020-11-02
CN2020112054239 2020-11-02
PCT/CN2020/134658 WO2021115286A1 (zh) 2019-12-10 2020-12-08 一种可用作shp2抑制剂的含氮杂原子的六元并五元芳环衍生物

Publications (1)

Publication Number Publication Date
CN114829362A true CN114829362A (zh) 2022-07-29

Family

ID=76329541

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080069976.8A Pending CN114829362A (zh) 2019-12-10 2020-12-08 一种可用作shp2抑制剂的含氮杂原子的六元并五元芳环衍生物

Country Status (3)

Country Link
CN (1) CN114829362A (zh)
TW (1) TW202130641A (zh)
WO (1) WO2021115286A1 (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023002248A (es) 2020-09-03 2023-05-16 Revolution Medicines Inc Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2.
CR20230165A (es) 2020-09-15 2023-06-02 Revolution Medicines Inc Derivados indólicos como inhibidores de ras en el tratamiento del cáncer
BR112023022819A2 (pt) 2021-05-05 2024-01-16 Revolution Medicines Inc Compostos, composição farmacêutica, conjugados e métodos para tratar câncer em um sujeito, para tratar um distúrbio e para inibir uma proteína ras em uma célula
CN117616031A (zh) 2021-05-05 2024-02-27 锐新医药公司 用于治疗癌症的ras抑制剂
WO2022235866A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
IL309984A (en) 2021-07-09 2024-03-01 Kanaph Therapeutics Inc SHP2 inhibitor and use thereof
CA3224341A1 (en) 2021-09-01 2023-03-09 Novartis Ag Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
CN114920759A (zh) * 2022-05-18 2022-08-19 江南大学 杂环-三氮唑并噻二唑杂环串联化合物、合成方法、药物组合物及用途
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662163A1 (fr) * 1990-05-16 1991-11-22 Lipha Nouvelles 8-amino-1,2,4-triazolo(4,3-a) pyrazines, procedes de preparation et medicaments les contenant.
US6187777B1 (en) * 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
CN1692115A (zh) * 2002-12-26 2005-11-02 大正制药株式会社 环状氨基取代的吡咯并嘧啶和吡咯并吡啶衍生物
US20130053371A1 (en) * 2010-01-22 2013-02-28 Centro Nacional De Investigaciones Oncológicas (Cnio) Inhibitors of pi3 kinase
CN103328482A (zh) * 2011-01-03 2013-09-25 韩美药品株式会社 用于调节g蛋白-偶联受体的新双环化合物
CN103415520A (zh) * 2011-12-21 2013-11-27 江苏恒瑞医药股份有限公司 吡咯并六元杂芳环类衍生物、其制备方法及其在医药上的应用
US20150284398A1 (en) * 2014-04-04 2015-10-08 Duquesne University Of The Holy Spirit Substituted Bicyclic Pyrimidine Compounds with Tubulin and Multiple Receptor Inhibition
CN106488919A (zh) * 2014-06-25 2017-03-08 武田药品工业株式会社 3‑取代的2‑氨基吲哚衍生物
CN107567452A (zh) * 2015-04-29 2018-01-09 詹森药业有限公司 咪唑并哌嗪和吡唑并嘧啶以及它们作为ampa受体调节剂的用途
WO2019040102A1 (en) * 2017-08-22 2019-02-28 Gilead Sciences, Inc. THERAPEUTIC HETEROCYCLIC COMPOUNDS
US20190290649A1 (en) * 2018-03-21 2019-09-26 Synblia Therapeutics, Inc. Shp2 inhibitors and uses thereof
US20190307745A1 (en) * 2016-09-22 2019-10-10 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of use thereof
CN110446709A (zh) * 2017-01-23 2019-11-12 锐新医药公司 作为变构shp2抑制剂的二环化合物

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662163A1 (fr) * 1990-05-16 1991-11-22 Lipha Nouvelles 8-amino-1,2,4-triazolo(4,3-a) pyrazines, procedes de preparation et medicaments les contenant.
US6187777B1 (en) * 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
CN1692115A (zh) * 2002-12-26 2005-11-02 大正制药株式会社 环状氨基取代的吡咯并嘧啶和吡咯并吡啶衍生物
US20130053371A1 (en) * 2010-01-22 2013-02-28 Centro Nacional De Investigaciones Oncológicas (Cnio) Inhibitors of pi3 kinase
CN103328482A (zh) * 2011-01-03 2013-09-25 韩美药品株式会社 用于调节g蛋白-偶联受体的新双环化合物
CN103415520A (zh) * 2011-12-21 2013-11-27 江苏恒瑞医药股份有限公司 吡咯并六元杂芳环类衍生物、其制备方法及其在医药上的应用
US20150284398A1 (en) * 2014-04-04 2015-10-08 Duquesne University Of The Holy Spirit Substituted Bicyclic Pyrimidine Compounds with Tubulin and Multiple Receptor Inhibition
CN106488919A (zh) * 2014-06-25 2017-03-08 武田药品工业株式会社 3‑取代的2‑氨基吲哚衍生物
CN107567452A (zh) * 2015-04-29 2018-01-09 詹森药业有限公司 咪唑并哌嗪和吡唑并嘧啶以及它们作为ampa受体调节剂的用途
US20190307745A1 (en) * 2016-09-22 2019-10-10 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of use thereof
CN110446709A (zh) * 2017-01-23 2019-11-12 锐新医药公司 作为变构shp2抑制剂的二环化合物
WO2019040102A1 (en) * 2017-08-22 2019-02-28 Gilead Sciences, Inc. THERAPEUTIC HETEROCYCLIC COMPOUNDS
US20190290649A1 (en) * 2018-03-21 2019-09-26 Synblia Therapeutics, Inc. Shp2 inhibitors and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JEFFREY T. BAGDANOFF，等: "Optimization of Fused Bicyclic Allosteric SHP2 Inhibitors" *
WANG, JIAN-XIN，等: "Palladium-Catalyzed Direct Heck Arylation of Dual π-Deficient/π-Excessive Heteroaromatics. Synthesis of C-5 Arylated Imidazo[1,5-a]pyrazines" *

Also Published As

Publication number Publication date
TW202130641A (zh) 2021-08-16
WO2021115286A1 (zh) 2021-06-17

Similar Documents

Publication Publication Date Title
CN114829362A (zh) 一种可用作shp2抑制剂的含氮杂原子的六元并五元芳环衍生物
US10844079B2 (en) Spiro aromatic ring compound and application thereof
JP7265275B2 (ja) Ｓｈｐ２阻害剤およびその使用
KR20210097144A (ko) 피리미딘 및 5-원 질소 헤테로사이클 유도체, 이의 제조 방법, 및 이의 의학적 용도
EP2558468B1 (en) 5, 7-substituted-imidazo [1,2-c] pyrimidines as inhibitors of jak kinases
AU2011291185C1 (en) Pyrrolopyrimidine compounds and uses thereof
AU2007286808B2 (en) Aza-benzofuranyl compounds and methods of use
AU2015276264B2 (en) Indolizine derivatives as phosphoinositide 3-kinases inhibitors
JP5350277B2 (ja) Ｐｉ３ｋ阻害剤としてのピロロピリミジン誘導体及びその用途
US11919902B2 (en) Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors
CA3189912A1 (en) Bicyclic compounds, compositions and use thereof
WO2014100540A1 (en) Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors
KR20140139023A (ko) 암을 치료하기 위한 6-(4-(1-아미노-3-하이드록시사이클로부틸)페닐)-5-페닐(퓨로, 싸이에노 또는 피롤로)[2,3-d]피리미딘-4-온 유도체
KR20160086930A (ko) 피롤로피롤론 유도체 및 bet 억제제로서의 그의 용도
CN116249696A (zh) 嘧啶酮类化合物及其用途
KR20240041340A (ko) 피롤로피리미딘 유도체 화합물 및 이의 용도
EP3028703B1 (en) Piperidine derivatives as wnt signaling inhibitor
TW201305181A (zh) 酞嗪酮類衍生物、其製備方法及其在醫藥上的應用
AU2015201991A1 (en) 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of JAK kinases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination